BMS Revenues Soar, But High-Flying Revlimid Is A Big Driver

First Generic Due In 2022; How Will Bristol Fill $12.1bn Gap?

 
• By Mandy Jackson
  
Airliner in flight
Revlimid generated $12.1bn in 2020 sales as Bristol's top-selling product • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business